The correlation between PSMA PET/CT uptake and [177Lu]Lu-PSMA-I&T absorbed dose in Metastatic Castration-Resistant Prostate Cancer Patients.

被引：0
|
作者：
Kalloe, V. [1 ]
Owers, E. C. [1 ]
de Boer, M. M. [1 ]
Rijkhorst, E. [1 ]
Aalbersberg, E. A. [1 ]
Dotinga, M. [1 ]
机构：
[1] Antoni van Leeuwenhoek, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-286
引用
收藏
页码：S424 / S424
页数：1
相关论文
共 50 条
  • [31] 177Lu -PSMA-I&T PSMA radioligand therapy in metastatic castration - resistant prostate cancer: First clinical trial in Asia
    Bu, Ting
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S528
  • [32] Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
    Nicolai Mader
    Christina Nguyen Ngoc
    Bilge Kirkgöze
    Justus Baumgarten
    Daniel Groener
    Konrad Klimek
    Christian Happel
    Nikolaos Tselis
    Felix K. H. Chun
    Frank Grünwald
    Amir Sabet
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1811 - 1821
  • [33] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
  • [34] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Justin Ferdinandus
    John Violet
    Shahneen Sandhu
    Rodney J. Hicks
    Aravind S. Ravi Kumar
    Amir Iravani
    Grace Kong
    Tim Akhurst
    Sue Ping Thang
    Declan G. Murphy
    Scott Williams
    Michael S. Hofman
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2322 - 2327
  • [35] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Ferdinandus, Justin
    Violet, John
    Sandhu, Shahneen
    Hicks, Rodney J.
    Ravi Kumar, Aravind S.
    Iravani, Amir
    Kong, Grace
    Akhurst, Tim
    Thang, Sue Ping
    Murphy, Declan G.
    Williams, Scott
    Hofman, Michael S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2322 - 2327
  • [36] Preliminary Results of Lu-177 PSMA I&T Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Hekimsoy, T.
    Gorur, G. Daglioz
    Isgoren, S.
    Demir, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S592 - S593
  • [37] Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer
    Eiber, Matthias
    Heck, Matthias
    Tauber, Robert
    Rauscher, Isabel
    D'Alessandria, Calogero
    Maurer, Tobias
    Retz, Margitta
    Wester, Hans
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [38] The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
    Scarpa, Lorenza
    Buxbaum, Sabine
    Kendler, Dorota
    Fink, Katharina
    Bektic, Jasmin
    Gruber, Leonhard
    Decristoforo, Clemens
    Uprimny, Christian
    Lukas, Peter
    Horninger, Wolfgang
    Virgolini, Irene
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (05) : 788 - 800
  • [39] LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Kostos, Louise
    Buteau, James P.
    Kong, Grace
    Opar, Petra
    Di Lulio, Juliana
    Fahey, Michael
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 77 - 77
  • [40] The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
    Lorenza Scarpa
    Sabine Buxbaum
    Dorota Kendler
    Katharina Fink
    Jasmin Bektic
    Leonhard Gruber
    Clemens Decristoforo
    Christian Uprimny
    Peter Lukas
    Wolfgang Horninger
    Irene Virgolini
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 788 - 800
12345